NSAIDs vs placebo
Minor bleeding · people with superficial thrombophlebitis of the leg
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
3,234 questions · 3,357 findings · 396 reviews
No studies found 803 · 23.9%GRADE not reported 270 · 8%Very low 757 · 22.5%Low 859 · 25.6%Moderate 486 · 14.5%High 182 · 5.4%
Fondaparinux vs placebo
Minor bleeding · people with ST of the leg
Fondaparinux showed no clear difference in minor bleeding compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.49 [0.53, 4.17]1 study · 2987 participantsModerate
Intervention not reported
Minor maternal morbidity · nurses, midwives, physicians
The intervention showed no clear difference in minor maternal morbidity (high certainty).
1 finding from 1 review
- Non‐clinical interventions for reducing unnecessary caesarean section 2018 · Cochrane Headline outcomes onlyRD 0.3Studies not reportedHigh
Intervention not reported
Minor neonatal morbidity · nurses, midwives, physicians
The intervention showed no clear difference in minor neonatal morbidity (high certainty).
1 finding from 1 review
- Non‐clinical interventions for reducing unnecessary caesarean section 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedHigh
Vitamin K antagonists vs no VKA
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
- Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes onlyRR 0.69 [0.38, 1.26]2 studies · 1026 participantsLow
Low molecular weight heparin vs vitamin K antagonist (VKA)
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
- Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes onlyRR 0.95 [0.2, 4.61]1 study · 234 participantsVery low
Low molecular weight heparin vs no LMWH
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in minor bleeding (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
- Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes onlyRR 1.35 [0.62, 2.92]2 studies · 544 participantsLow
Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis
Minor bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.83 [0.57, 1.23]4 studies · 1055 participantsLow
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.58 [1.15, 2.16]5 studies · 2854 participantsModerate
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.37 [0.41, 4.64]2 studies · 1495 participantsVery low
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.03 [0.04, 25.97]2 studies · 1495 participantsVery low
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor lower GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.54 [0.72, 3.27]2 studies · 1495 participantsLow
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor non‐GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 2.37 [1.44, 3.89]2 studies · 1495 participantsModerate
Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis
Minor bleeding ‐ not reported · people with cancer with VTE receiving secondary prophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis
Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.78 [0.47, 1.27]4 studies · 1712 participantsVery low
Intervention not reported
Minor adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
- no estimate extracted8 studies · 701 participantsLow
Intervention not reported
Adeno carcinoma in situ (AIS) associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower adeno carcinoma in situ (AIS) associated with HPV16/18 (high certainty).
1 finding from 1 review
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes onlyRR 0.36 [0.17, 0.78]2 studies · 34562 participantsHigh
LMWH prophylaxis vs fondaparinux prophylaxis
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for perioperative thromboprophylaxis in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.83 [0.34, 2.05]2 studies · 398 participantsLow
LMWH prophylaxis vs UFH
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor bleeding compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
- Anticoagulation for perioperative thromboprophylaxis in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.01 [0.76, 1.33]2 studies · 1194 participantsModerate
Lower vs higher oxygen concentrations titrated to target oxygen saturations during resuscitation of preterm infants at birth
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · preterm infants
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
- Lower versus higher oxygen concentrations titrated to target oxygen saturations during resuscitation of preterm… 2018 · Cochrane Headline outcomes onlyRR 0.57 [0.24, 1.36]4 studies · 453 participantsLow